NAD(P)H dehydrogenase, quinone 2

NQO2
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1QR2, 1SG0, 1XI2, 1ZX1, 2BZS, 2QMY, 2QMZ, 2QR2, 2QWX, 2QX4, 2QX6, 2QX8, 2QX9, 3FW1, 3G5M, 3GAM, 3NFR, 3NHF, 3NHJ, 3NHK, 3NHL, 3NHP, 3NHR, 3NHS, 3NHU, 3NHW, 3NHY, 3O2N, 3O73, 3OVM, 3OWH, 3OWX, 3OX1, 3OX2, 3OX3, 3TE7, 3TEM, 3TZB, 3UXE, 3UXH, 4FGJ, 4FGK, 4FGL, 4GQI, 4GR9, 4QOD, 4QOE, 4QOF, 4QOG, 4QOH, 4QOI, 4QOJ, 4U7F, 4U7G, 4U7H, 4XDG, 4XDH, 4ZVL, 4ZVM, 4ZVK, 5LBT, 5LBU, 5BUC, 4ZVN
Identifiers
Aliases	NQO2, Nqo2, NMO2, Nmor2, Ox2, DHQV, DIA6, QR2, NAD(P)H quinone dehydrogenase 2
External IDs	MGI: 104513 HomoloGene: 696 GeneCards: NQO2
Gene ontology Molecular function • electron carrier activity • oxidoreductase activity • NADPH dehydrogenase (quinone) activity • protein binding • metal ion binding Cellular component • cytoplasm • extracellular exosome • nucleoplasm Biological process • memory • oxidation-reduction process • positive regulation of neuron apoptotic process • positive regulation of vascular smooth muscle cell proliferation • positive regulation of ERK1 and ERK2 cascade • positive regulation of reactive oxygen species metabolic process Sources:Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	4835	18105
Ensembl	ENSG00000124588	ENSMUSG00000046949
UniProt	P16083	Q9JI75
RefSeq (mRNA)	NM_000904 NM_001290221 NM_001290222 NM_001318940	NM_001163239 NM_001163241 NM_001163242 NM_020282
RefSeq (protein)	NP_000895.2 NP_001277150.1 NP_001305869.1	NP_001156713.1 NP_001156714.1 NP_064678.1
Location (UCSC)	Chr 6: 2.99 – 3.03 Mb	Chr 13: 33.96 – 33.99 Mb
PubMed search	[1]	[2]
Wikidata

View/Edit Human

View/Edit Mouse

NAD(P)H dehydrogenase, quinone 2, also known as NQO2 or QR2, is a human gene. It is a phase II detoxification enzyme which can carry out two or four electron reductions. Its mechanism of reduction is via a covalently bound zinc ion and a cocrystalized FAD. NQO2 contains two chains homologous in AA sequence but 7% different in structure. As a result, NQO2 contains two similar yet unique active sites. An important function of NQO2 is its activation on NRH. NQO2 can be inhibited by resveratrol.^[3]

References

1. "Human PubMed Reference:".
2. "Mouse PubMed Reference:".
3. "Entrez Gene: NQO2 NAD(P)H dehydrogenase, quinone 2".

Further reading

• Jaiswal AK, Burnett P, Adesnik M, McBride OW (1990). "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6.". Biochemistry. 29 (7): 1899–906. doi:10.1021/bi00459a034. PMID 1691923.
• Jaiswal AK (1994). "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression.". J. Biol. Chem. 269 (20): 14502–8. PMID 8182056.
• Zhao Q, Yang XL, Holtzclaw WD, Talalay P (1997). "Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase)". Proc. Natl. Acad. Sci. U.S.A. 94 (5): 1669–74. doi:10.1073/pnas.94.5.1669. PMC 19974. PMID 9050836.
• Wu K, Knox R, Sun XZ, et al. (1997). "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.". Arch. Biochem. Biophys. 347 (2): 221–8. doi:10.1006/abbi.1997.0344. PMID 9367528.
• Foster CE, Bianchet MA, Talalay P, et al. (1999). "Crystal structure of human quinone reductase type 2, a metalloflavoprotein.". Biochemistry. 38 (31): 9881–6. doi:10.1021/bi990799v. PMID 10433694.
• Jaiswal AK, Bell DW, Radjendirane V, Testa JR (1999). "Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms.". Pharmacogenetics. 9 (3): 413–8. doi:10.1097/00008571-199906000-00020. PMID 10471077.
• Harada S, Fujii C, Hayashi A, Ohkoshi N (2001). "An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2.". Biochem. Biophys. Res. Commun. 288 (4): 887–92. doi:10.1006/bbrc.2001.5868. PMID 11688992.
• Strassburg A, Strassburg CP, Manns MP, Tukey RH (2002). "Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue.". Mol. Pharmacol. 61 (2): 320–5. doi:10.1124/mol.61.2.320. PMID 11809856.
• Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
• Okubo T, Harada S, Higuchi S, Matsushita S (2004). "Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms.". Alcohol. Clin. Exp. Res. 27 (8 Suppl): 68S–71S. doi:10.1097/01.ALC.0000078616.63296.41. PMID 12960511.
• Ostrousky O, Meged S, Loewenthal R, et al. (2004). "NQO2 gene is associated with clozapine-induced agranulocytosis.". Tissue Antigens. 62 (6): 483–91. doi:10.1046/j.1399-0039.2003.00133.x. PMID 14617031.
• Harada S, Tachikawa H, Kawanishi Y (2005). "A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia.". Psychiatr. Genet. 13 (4): 205–9. doi:10.1097/01.ypg.0000071601.59979.47. PMID 14639047.
• Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
• Kwiek JJ, Haystead TA, Rudolph J (2004). "Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.". Biochemistry. 43 (15): 4538–47. doi:10.1021/bi035923w. PMID 15078100.
• Buryanovskyy L, Fu Y, Boyd M, et al. (2004). "Crystal structure of quinone reductase 2 in complex with resveratrol.". Biochemistry. 43 (36): 11417–26. doi:10.1021/bi049162o. PMID 15350128.
• Wang W, Jaiswal AK (2005). "Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter.". Free Radic. Biol. Med. 37 (8): 1231–43. doi:10.1016/j.freeradbiomed.2004.06.042. PMID 15451063.
• Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
• Hsieh TC, Wang Z, Hamby CV, Wu JM (2005). "Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53.". Biochem. Biophys. Res. Commun. 334 (1): 223–30. doi:10.1016/j.bbrc.2005.06.073. PMID 15993843.
• Fu Y, Buryanovskyy L, Zhang Z (2005). "Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954.". Biochem. Biophys. Res. Commun. 336 (1): 332–8. doi:10.1016/j.bbrc.2005.08.081. PMID 16129418.
• Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network.". Nature. 437 (7062): 1173–8. doi:10.1038/nature04209. PMID 16189514.